Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.80% | -19.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.80% | -19.38% | |||
| Cost of Revenue | -11.91% | -29.37% | |||
| Gross Profit | -11.70% | -8.67% | |||
| SG&A Expenses | -4.74% | 7.10% | |||
| Depreciation & Amortization | 2.97% | -22.20% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.83% | -11.71% | |||
| Operating Income | -12.62% | -40.72% | |||
| Income Before Tax | -12.25% | -45.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.25% | -45.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.25% | -45.75% | |||
| EBIT | -12.62% | -40.72% | |||
| EBITDA | -16.59% | -110.76% | |||
| EPS Basic | -13.22% | -46.84% | |||
| Normalized Basic EPS | -12.84% | -47.30% | |||
| EPS Diluted | -7.95% | -54.01% | |||
| Normalized Diluted EPS | -12.84% | -47.30% | |||
| Average Basic Shares Outstanding | -0.88% | -0.76% | |||
| Average Diluted Shares Outstanding | -0.88% | -0.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
